ZYME
Zymeworks Inc.
Company Overview
| Mkt Cap | $1.27B | Price | $26.81 |
| Volume | 389.23K | Change | +3.10% |
| P/E Ratio | -10.3 | Open | $26.48 |
| Revenue | $76.3M | Prev Close | $26.00 |
| Net Income | $-122.7M | 52W Range | $9.03 - $28.49 |
| Div Yield | N/A | Target | $40.08 |
| Overall | 54 | Value | 60 |
| Quality | 42 | Technical | 60 |
No chart data available
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Latest News
Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZYME | $26.81 | +3.1% | 389.23K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |